Results from an open-label extension study of etanercept in ankylosing spondylitis

被引：35

作者：

Davis, J ^{[1
]}

Webb, A ^{[1
]}

Lund, S ^{[1
]}

Sack, K ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2004年 / 51卷 / 02期

关键词：

D O I：

10.1002/art.20241

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：302 / 304

页数：3

共 7 条

[1] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[2]

CALIN A, 1994, J RHEUMATOL, V21, P2281

[3] Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].

Davis, JC ;

van der Heijde, D ;

Braun, J ;

Dougados, M ;

Cush, J ;

Clegg, DO ;

Kivitz, A ;

Fleischmann, R ;

Inman, R ;

Tsuji, W .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236

[4] Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α [J].

Gorman, JD ;

Sack, KE ;

Davis, JC .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1349-1356

[5]

JENKINSON TR, 1994, J RHEUMATOL, V21, P1694

[6] A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis [J].

Maksymowych, WP ;

Jhangri, GS ;

Fitzgerald, AA ;

LeClercq, S ;

Chiu, P ;

Yan, A ;

Skeith, KJ ;

Aaron, SL ;

Homik, J ;

Davis, P ;

Sholter, D ;

Russell, AS .

ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :766-773

[7]

van der Heijde D, 1999, J RHEUMATOL, V26, P951

← 1 →